Answer
Oct 23, 2025 - 11:23 AM
Tagrisso (osimertinib) is a medication used to treat certain types of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The survival duration for patients on Tagrisso can vary based on individual factors, including the stage of cancer and patient health. Clinical trials have shown median overall survival rates of around 38-39 months for patients with advanced NSCLC treated with Tagrisso as a first-line therapy, but outcomes can differ widely among individuals.
